イノベーションに情熱を。 ひとに思いやりを。



ASCO 2018 Summary of Presentation

May 16, 2018


ASCO: Accepted Presentations

Daiichi-Sanky

- Oral presentations
 - DS-8201
 - Pexidartinib
- Poster discussions
 - > U3-1402
 - Quizartinib
 - > DS-3032
- Poster presentations
 Trial-in-Progress
 DS-8201
 U3-1402
 - ✓ DS-1062







- Abstract No: 2501
- Oral presentation on June 1^{st,} 2:45 PM 5:45 PM

U3-1402 Ph1 study (breast cancer) update

- Abstract No: 2512
- Poster discussion on June 4th, 3:00 PM 4:15 PM

Results will be updated at actual presentation

ASCO Presentations: DS-8201



DSI Compound	Presentation Type	Tumor Type	Lead Author	Title	Session
DS-8201	Oral Presentation	HER2-positive solid tumors	Hiroji Iwata	Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts	Abstract No: 2501 Session Name: Developmental Therapeutics- Clinical Pharmacology and Experimental Therapeutics Date: June 1, 2018 Time: 2:45 PM – 5:45 PM Location: S406
DS-8201	Trial-in- Progress Poster Presentation	HER2-positive metastatic breast cancer	Jose Baselga	A phase 2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-positive, unresectable and/or metastatic breast cancer previously treated with T- DM1	Abstract No.: TPS1102 Session Name: Breast Cancer- Metastatic Date: June 2, 2018 Time: 8:00 AM – 11:30 AM Location: Hall A
DS-8201	Trial-in- Progress Poster Presentation	HER2-positive gastric cancer	Kensei Yamaguchi	A randomized, phase 2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2- expressing gastric cancer	Abstract No: TPS4133 Session Name: Gastrointestinal (Noncolorectal) Cancer Date: June 3, 2018 Time: 8:00 AM – 11:30 AM Location: Hall A

ASCO Presentations: ADC Franchise



DSI Compound	Presentation Type	Tumor Type	Lead Author	Title	Session
U3-1402	Poster Discussion	Metastatic breast cancer	Takahiro Kogawa	Single Agent Activity of U3-1402, a HER3- Targeting Antibody-Drug Conjugate, in Breast Cancer Patients: Phase 1 Dose Escalation Study	Abstract No: 2512 Session Name: Developmental Therapeutics-Clinical Pharmacology and Experimental Therapeutics Poster Discussion Date: June 4, 2018 Time: 3:00 PM – 4:15 PM Location: S406 Poster Session Date: June 4, 2018 Time: 8:00 AM – 11:30 AM Location: Hall A
U3-1402	Trial-in- Progress Poster Presentation	Metastatic or unresectable EGFR-mutant NSCLC	Pasi A. Jänne	Phase 1 Study of the Anti-HER3 Antibody Drug Conjugate U3-1402 in Metastatic or Unresectable EGFR-Mutant NSCLC	Abstract No.: TPS9110 Session Name: Lung Cancer—Non-Small Cell Metastatic Date: June 3, 2018 Time: 8:00 AM – 11:30 AM Location: Hall A
DS-1062	Trial-in- Progress Poster Presentation	Advanced solid tumors	Jacob M. Sands	First-in-human phase 1 study of DS-1062a in patients (pts) with advanced solid tumors (AST)	Abstract No: TPS2605 Session Name: Developmental Therapeutics- Clinical Pharmacology and Experimental Therapeutics Date: June 4, 2018 Time: 8:00 AM – 11:30 AM Location: Hall A

ASCO Presentations: AML Franchise



DSI Compound	Presentation Type	Tumor Type	Lead Author	Title	Session
Quizartinib	Poster Discussion	FLT3-ITD- mutated relapsed/refracto ry acute myeloid leukemia (AML)	Mark J. Levis	Post hoc exploratory analysis of two phase 2 trials of quizartinib monotherapy in patients (pts) with FLT3-ITD- mutated (mu) relapsed/refractory (R/R) AML with or without prior 1st-generation FLT3 tyrosine kinase inhibitors (TKI) treatment	Abstract No.: 7017 Session Name: Hematologic Malignancies-Leukemia, Myelodysplastic Syndromes, and Allotransplant Poster Discussion Date: June 4, 2018 Time: 11:30 AM – 12:45 PM Location: E450 Poster Session Date: June 4, 2018 Time: 8:00 AM – 11:30 AM Location: Hall A
DS-3032	Poster Discussion	Advanced solid tumors and lymphomas	Todd M. Bauer	A phase 1 study of the MDM2 inhibitor DS-3032b in patients with well/de- differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L)	Abstract No: 11514 Session Name: Sarcoma Poster Discussion Date: June 2, 2018 Time: 3:00 PM – 4:15 PM Location: S404 Poster Session Date: June 2, 2018 Time: 8:00 AM – 11:30 AM Location: Hall A

ASCO Presentations: Breakthrough Science



DSI Compound	Presentation Type	Tumor Type	Lead Author	Title	Session
Pexidartinib	Oral Presentation	Tenosynovial giant- cell tumor (TGCT)	William D. Tap	Final results of ENLIVEN: a global, double-blind, randomized, placebo-controlled, Phase 3 study of pexidartinib in advanced tenosynovial giant cell tumor (TGCT)	Abstract No: 11502 Session Name: Sarcoma Date: June 4, 2018 Time: 8:00 AM – 11:00 AM Location: S100a

Contact address regarding this material

Daiichi Sankyo Co., Ltd. Corporate Communications Department TEL: +81-3-6225-1126 Email: DaiichiSankyoIR@daiichisankyo.co.jp